Key Takeaways
- AP reported on Oct. 15, 2026, that federal health officials were advancing a plan to broaden access to peptides.
- An FDA advisory committee recommended six peptides, including BPC-157, for the 503A bulk drugs list on July 23 and 24.
- FDA scientists unanimously recommended against four of those six, citing effectively an absence of human clinical data.
- The committee's votes are advice. McDermott Law reported on July 27 that FDA would start notice-and-comment rulemaking, a formal public-comment process, to consider adding the six to the list.
AP reported on Oct. 15, 2026, that the Trump administration was advancing a plan to broaden access to peptides, which AP describes as unproven injectable drugs. In July, the Pharmacy Compounding Advisory Committee, an FDA advisory panel, recommended six peptides, including BPC-157, for the 503A list that governs what compounding pharmacies may legally prepare. FDA's own scientists had unanimously opposed four of the six.
What the advisory committee recommended in July
On July 23 and 24, 2026, the Pharmacy Compounding Advisory Committee recommended adding BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax to the 503A bulk drugs list. It declined to recommend emideltide, McDermott Law reported. If FDA adopts the recommendations, compounding pharmacies could prepare those peptides for patients who hold a valid prescription.
McDermott Law reported on July 27 that Category 1 products are subject to FDA enforcement discretion and may be used in compounding, although they are not technically part of the official bulk drugs lists. It also reported that products in Categories 2 and 3 were not afforded this discretion and could not be used in compounding without fear of reprisal by the FDA. McDermott Law also expected FDA to use some form of informal enforcement discretion in the interim, while formal rulemaking was expected to proceed.
Where FDA's scientists reached the opposite conclusion
FDA's own scientists disagreed with the panel. The American Journal of Managed Care (AJMC) reports that the agency's scientists unanimously recommended against adding BPC-157, TB-500, KPV and MOTS-c, because there is effectively an absence of human clinical data. The same account reports that BPC-157's only human clinical evidence is a decades-old, never-published meeting abstract. AJMC's summary of the meeting says advisers overrode their own scientists to back six peptides.
AJMC's summary and McDermott Law's report, read together, show that the committee recommended all four peptides that FDA's scientists opposed. The panel met at FDA's White Oak campus in Silver Spring, Maryland, from July 23 to 24. Related WYDE coverage: Superpower's peptide library.
Kennedy's February plan and the telehealth companies that announced plans to offer peptides
AJMC reports that on Feb. 27, 2026, Kennedy announced that about 14 of the 19 peptides on FDA's Category 2 restricted compounding list would move back to Category 1. AP identifies Robert F. Kennedy Jr. as the Health and Human Services secretary. AJMC reported that the reclassification was expected to take effect by April 23, 2026. The same account reports that Category 1 status would not amount to FDA approval, which would mean no validated indications, standardized dosing, or established safety and efficacy data.
AP reported that Hims & Hers and Noom had each announced plans to offer peptides to their customers if the federal government eases access. Wall Street analysts estimate the market could be worth $2 billion to $3 billion, AP reports. Brigham Buhler, a wellness clinic operator who sells peptides through an online service, posted on X: "This isn't about whether you're for or against peptides." Buhler framed the broader question as one of medical freedom. Rachel Strauss, founder and CEO of a pharmacy benefit consulting firm, spoke to AJMC from the payer and drug-access side of the industry rather than as a clinician, saying: "Patient demand is not necessarily clinical evidence, but you can't pretend that patient demand doesn't exist." Strauss added that patient demand is not a safety strategy either.
People Also Ask
Are BPC-157 and other peptides FDA approved?
AJMC reports that moving a peptide to Category 1 would not constitute FDA approval for BPC-157 or any other peptide in the group of about 14 that Robert F. Kennedy Jr.'s February plan would move. AP describes peptides as a class of unproven injectable drugs.
What did the FDA advisory committee recommend for BPC-157 in July?
On July 23 and 24, 2026, the Pharmacy Compounding Advisory Committee recommended adding BPC-157 to the 503A bulk drugs list. That recommendation is advice, and McDermott Law reported on July 27 that FDA would start notice-and-comment rulemaking to consider adding BPC-157 to the list.
How much human evidence supports BPC-157?
AJMC reports that BPC-157's only human clinical evidence is a decades-old, never-published meeting abstract. FDA's scientists unanimously recommended against listing BPC-157, citing effectively an absence of human clinical data.
Why are telehealth companies interested in peptides?
AP reported that Hims & Hers and Noom had each announced plans to offer peptides to customers if the federal government eases access. Wall Street analysts estimate the market could be worth $2 billion to $3 billion, AP reports.
Sources: AP via KSAT, The American Journal of Managed Care, McDermott Law.